Literature DB >> 33094626

Endocrine disruptors, obesity, and cytokines - how relevant are they to PCOS?

M Šimková1, J Vítků, L Kolátorová, J Vrbíková, M Vosátková, J Včelák, M Dušková.   

Abstract

As environmental and genetic components contribute to the PCOS expression, we compared levels of endocrine disruptors, steroid hormones, cytokines, and metabolic parameters in twenty healthy, nine normal-weight PCOS women, and ten obese PCOS women. Steroid hormones, bisphenols (BPA, BPS, BPF, BPAF) and parabens (methyl-, ethyl-, propyl-, butyl-, benzyl-parabens) were measured by liquid chromatography-tandem mass spectrometry. Differences between the groups were assessed using the Mann-Whitney U test. Spearman correlation coefficients were calculated for the individual parameters relationship. Significantly higher levels of BPA, anti-Müllerain hormone, lutropine, lutropine/folitropine ratio, testosterone, androstenedione, 7beta-OH-epiandrosterone, and cytokines (IL-6, VEGF, PDGF-bb), were found in normal-weight PCOS women compared to controls. Between normal-weight and obese PCOS women, there were no differences in hormonal, but in metabolic parameters. Obese PCOS women had significantly higher insulin resistance, fatty-liver index, triglycerides, cytokines (IL-2, IL-13, IFN-gamma). In healthy, but not in PCOS, women, there was a positive correlation of BPA with testosterone, SHBG with lutropine, and folitropine, while testosterone negatively correlated with SHBG. In obese women with PCOS, insulin resistance negatively correlated with SHBG and estradiol. No differences were observed in the paraben exposure. Levels of BPA were higher in PCOS women, indicating its role in the etiology. Obesity significantly worsens the symptoms.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33094626      PMCID: PMC8603732          DOI: 10.33549/physiolres.934521

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  68 in total

1.  Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic.

Authors:  Chandrika N Wijeyaratne; Ruwanthi de A Seneviratne; Shamalka Dahanayake; Vindya Kumarapeli; Ethusha Palipane; Nadeera Kuruppu; Chandrika Yapa; Rohini de A Seneviratne; Adam H Balen
Journal:  Hum Reprod       Date:  2010-11-23       Impact factor: 6.918

2.  Development and validation of LC-MS/MS method for quantification of bisphenol A and estrogens in human plasma and seminal fluid.

Authors:  Jana Vitku; Tereza Chlupacova; Lucie Sosvorova; Richard Hampl; Martin Hill; Jiri Heracek; Marie Bicikova; Luboslav Starka
Journal:  Talanta       Date:  2015-03-12       Impact factor: 6.057

3.  Determination of selected bisphenols, parabens and estrogens in human plasma using LC-MS/MS.

Authors:  Lucie Kolatorova Sosvorova; Tereza Chlupacova; Jana Vitku; Martin Vlk; Jiri Heracek; Luboslav Starka; David Saman; Marketa Simkova; Richard Hampl
Journal:  Talanta       Date:  2017-05-26       Impact factor: 6.057

Review 4.  Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth.

Authors:  Evanthia Diamanti-Kandarakis; Christina Piperi
Journal:  Hum Reprod Update       Date:  2005-07-01       Impact factor: 15.610

Review 5.  Industrial endocrine disruptors and polycystic ovary syndrome.

Authors:  E Palioura; E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  2013-12       Impact factor: 4.256

Review 6.  Endocrine disruptors and polycystic ovary syndrome: a focus on Bisphenol A and its potential pathophysiological aspects.

Authors:  Eleni Palioura; Eleni Kandaraki; Evanthia Diamanti-Kandarakis
Journal:  Horm Mol Biol Clin Investig       Date:  2014-03

Review 7.  Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure.

Authors:  Wade V Welshons; Susan C Nagel; Frederick S vom Saal
Journal:  Endocrinology       Date:  2006-05-11       Impact factor: 4.736

8.  Endocrine disruptors of the bisphenol and paraben families and bone metabolism.

Authors:  J Vitku; L Kolatorova; L Franekova; J Blahos; M Simkova; M Duskova; T Skodova; L Starka
Journal:  Physiol Res       Date:  2018-11-28       Impact factor: 1.881

9.  Handling of thermal receipts as a source of exposure to bisphenol A.

Authors:  Shelley Ehrlich; Antonia M Calafat; Olivier Humblet; Thomas Smith; Russ Hauser
Journal:  JAMA       Date:  2014-02-26       Impact factor: 56.272

10.  Bisphenol A concentration-dependently increases human granulosa-lutein cell matrix metalloproteinase-9 (MMP-9) enzyme output.

Authors:  Miguel A Dominguez; Maria A Petre; Michael S Neal; Warren G Foster
Journal:  Reprod Toxicol       Date:  2008-05-24       Impact factor: 3.143

View more
  5 in total

Review 1.  Androgens in SARS-CoV-2 coronavirus infections.

Authors:  L Stárka; M Dušková
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

Review 2.  Determination of Intraprostatic and Intratesticular Androgens.

Authors:  Markéta Šimková; Jiří Heráček; Pavel Drašar; Richard Hampl
Journal:  Int J Mol Sci       Date:  2021-01-05       Impact factor: 5.923

Review 3.  Polycystic ovary syndrome: Pathways and mechanisms for possible increased susceptibility to COVID-19.

Authors:  Ioannis Ilias; Spyridon Goulas; Lina Zabuliene
Journal:  World J Clin Cases       Date:  2021-04-26       Impact factor: 1.337

4.  The Association Between Genetically Predicted Systemic Inflammatory Regulators and Polycystic Ovary Syndrome: A Mendelian Randomization Study.

Authors:  Hanxiao Chen; Yaoyao Zhang; Shangwei Li; Yuanzhi Tao; Rui Gao; Wenming Xu; Yihong Yang; Kemin Cheng; Yan Wang; Lang Qin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-27       Impact factor: 5.555

5.  Association of Prx4, Total Oxidant Status, and Inflammatory Factors with Insulin Resistance in Polycystic Ovary Syndrome.

Authors:  Sahar Mazloomi; Nasrin Sheikh; Marzieh Sanoee Farimani; Shamim Pilehvari
Journal:  Int J Endocrinol       Date:  2021-06-22       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.